v3.25.2
Discontinued Operations - Not Classified as Held for Sale (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 11, 2025
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Assets            
TSA receivables, net (Note 6)   $ 114,530   $ 114,530   $ 11,010
Liabilities            
Accrued rebates, fees and reserves   96,814   96,814   164,867
Accrued and other current liabilities   14,179   14,179   60,288
Other liabilities, non-current   16,735   16,735   29,329
Convertible notes, non-current           228,229
Inventory       (18,474) $ (18,557)  
Accord BioPharma, Inc            
Assets            
TSA receivables, net (Note 6)   6,400   6,400    
Discontinued Operations Disposed of by Sale            
Assets            
Trade receivables, net   (10,273)   (10,273)    
Liabilities            
Accrued rebates, fees and reserves   95,062   95,062    
Loss on debt extinguishment   (10,286)   (10,286)    
Gain on Sale Transactions, net   339,102   339,102    
Discontinued Operations Disposed of by Sale | UDENYCA            
Liabilities            
Net gain $ 339,100     339,100    
Loss on debt extinguishment       10,300    
Assets Held For Sale            
Assets            
Trade receivables, net           102,365
Liabilities            
Accrued rebates, fees and reserves           163,771
Gain on Sale Transactions, net     $ 24,085   177,732  
Assets Held For Sale | UDENYCA            
Liabilities            
Accrued and other current liabilities           14,816
Other liabilities, non-current           15,667
Convertible notes, non-current           $ 228,229
Gain on Sale Transactions, net         177,700  
Inventory         15,500  
Disposal Group            
Liabilities            
Reimbursed for its costs and has recorded income   $ 1,700 $ 800 $ 1,800 $ 1,200